Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 3/20 | 0.46 |
| ▸ | CTSL | P07711 | 2/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.45 |
| ▸ | CASP3 | P42574 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15342315 | 1.00 | MDM4 (0.49) | MDM4TP53CTSBCTSLPTPN1 | |
| SCHEMBL30143778 | 0.95 | MDM4 (0.51) | MDM4TP53CTSBCTSLPTPN1 | |
| SCHEMBL29647845 | 0.94 | GPR132 (0.44) | MDM4TP53CTSBCTSLPTPN1 | |
| SCHEMBL3730261 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL29385457 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL119546 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL29540614 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL3728714 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL29816502 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 | |
| SCHEMBL30291630 | 0.91 | MDM4 (0.54) | MDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | claimed |
| CN-114478708-A | Solid phase synthesis method of ganirelix fragment | 南京汉欣医药科技有限公司 | 2022-05-13 | — | — | CN | claimed |
| CN-109575109-B | Method for preparing degarelix by fragment condensation | 兰州大学 | 2022-03-25 | — | — | CN | claimed |
| CN-114920804-B | Cetrorelix synthesis process capable of being directly used for pilot scale amplification | 厦门胜泽泰医药科技有限公司 | 2024-07-30 | — | — | CN | disclosed |
| CN-117683093-A | Method for solid phase synthesis of ganirelix by fragment method | 中肽生化有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114920804-A | Sitrorelix synthesis process capable of being directly used for pilot amplification | 厦门胜泽泰医药科技有限公司 | 2022-08-19 | — | — | CN | disclosed |
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | Fresenius Kabi Ipsum S.R.L. (IT) | 2022-06-09 | — | — | US | disclosed |
| CN-114478708-A | Solid phase synthesis method of ganirelix fragment | 南京汉欣医药科技有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-114456236-A | Preparation method of degarelix acetylated impurities | 深圳市健翔生物制药有限公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-109575109-B | Method for preparing degarelix by fragment condensation | 兰州大学 | 2022-03-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220177521-A1 | PROCESS FOR THE PREPARATION OF DEGARELIX | VIP, PEPD, SSTR4 | MDM4 1240/4885TP53 804/4885CTSB 423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.